Dyne Therapeutics, Inc. Stock Prediction and Forecast [DYN]

AI-generated source summary

The video analyzes Dyne Therapeutics (DYN) stock, downgrading it from "strong buy" to "hold". The analysis highlights the stock's recent significant gains, achieving 73.26% in 15 days with an average daily gain of 4.88%, despite the system assigning a score of zero, predicting high volatility and risk. It notes the stock's recent break through an upward trend, estimating a potential 53.6% change in the next three months, with returns ranging from a decline of 9.13% to an increase of 12.44%. The 12-month analysis projects a change of -37.7%, suggesting a future price range of 0.00 to 15.06. Analyst ratings average to "sell". On the last trading day, DYNE gained 41.18%, closing at 24.17, and volume has increased on the last day along with the price, which is considered to be a good technical signal. Support is now at $17.76. There are ongoing investor litigation inquiries. The suggested stop-loss is $22.90 (-5.24%). For trading on October 28th, expect Dyne Therapeutics to open down -$0.130 and start trading at $24.04.

AI-generated summary based on the source content.

Evidence and evaluation progress

1. Original source published

   28 Oct 2025, 02:59 UTC

   The analyst published the original source item.

2. Source recorded by Tahlil Plus

   18 May 2026, 20:23 UTC

   The public source was preserved as the evidence record for this case.

3. Market predictions extracted

   18 May 2026, 20:47 UTC

   1 eligible signal linked to this case.

4. Outcome tracking started

   02 Jul 2026, 02:10 UTC

   Tahlil Plus began monitoring the extracted predictions.

5. First prediction resolved

   02 Jul 2026, 02:10 UTC

   The first evaluable outcome in this case reached a terminal result.

6. Case evaluation completed

   02 Jul 2026, 02:10 UTC

   All evaluable predictions in this case reached terminal outcomes.